vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and SITIME Corp (SITM). Click either name above to swap in a different company.
SITIME Corp is the larger business by last-quarter revenue ($113.3M vs $62.1M, roughly 1.8× Cytek Biosciences, Inc.). SITIME Corp runs the higher net margin — 8.1% vs -70.9%, a 79.0% gap on every dollar of revenue. On growth, SITIME Corp posted the faster year-over-year revenue change (66.3% vs 8.1%). SITIME Corp produced more free cash flow last quarter ($13.0M vs $-1.8M). Over the past eight quarters, SITIME Corp's revenue compounded faster (85.2% CAGR vs 17.7%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
SiTime Corporation is a publicly traded fabless chipmaker based in Santa Clara, California that develops micro-electromechanical systems (MEMS), used for timing devices in electronics.
CTKB vs SITM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $113.3M |
| Net Profit | $-44.1M | $9.2M |
| Gross Margin | 52.9% | 56.4% |
| Operating Margin | -9.0% | 1.6% |
| Net Margin | -70.9% | 8.1% |
| Revenue YoY | 8.1% | 66.3% |
| Net Profit YoY | -557.1% | 148.7% |
| EPS (diluted) | — | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $113.3M | ||
| Q3 25 | $52.3M | $83.6M | ||
| Q2 25 | $45.6M | $69.5M | ||
| Q1 25 | $41.5M | $60.3M | ||
| Q4 24 | $57.5M | $68.1M | ||
| Q3 24 | $51.5M | $57.7M | ||
| Q2 24 | $46.6M | $43.9M | ||
| Q1 24 | $44.9M | $33.0M |
| Q4 25 | $-44.1M | $9.2M | ||
| Q3 25 | $-5.5M | $-8.0M | ||
| Q2 25 | $-5.6M | $-20.2M | ||
| Q1 25 | $-11.4M | $-23.9M | ||
| Q4 24 | $9.6M | $-18.8M | ||
| Q3 24 | $941.0K | $-19.3M | ||
| Q2 24 | $-10.4M | $-26.8M | ||
| Q1 24 | $-6.2M | $-28.7M |
| Q4 25 | 52.9% | 56.4% | ||
| Q3 25 | 52.7% | 53.5% | ||
| Q2 25 | 52.3% | 51.9% | ||
| Q1 25 | 48.6% | 50.3% | ||
| Q4 24 | 58.5% | 52.6% | ||
| Q3 24 | 56.3% | 51.1% | ||
| Q2 24 | 54.6% | 49.1% | ||
| Q1 24 | 51.3% | 53.5% |
| Q4 25 | -9.0% | 1.6% | ||
| Q3 25 | -17.6% | -19.2% | ||
| Q2 25 | -23.3% | -35.4% | ||
| Q1 25 | -36.1% | -46.6% | ||
| Q4 24 | 5.2% | -33.8% | ||
| Q3 24 | -8.2% | -43.1% | ||
| Q2 24 | -18.3% | -73.7% | ||
| Q1 24 | -23.9% | -106.1% |
| Q4 25 | -70.9% | 8.1% | ||
| Q3 25 | -10.5% | -9.6% | ||
| Q2 25 | -12.2% | -29.0% | ||
| Q1 25 | -27.5% | -39.6% | ||
| Q4 24 | 16.8% | -27.6% | ||
| Q3 24 | 1.8% | -33.5% | ||
| Q2 24 | -22.4% | -61.0% | ||
| Q1 24 | -13.8% | -86.9% |
| Q4 25 | — | $0.44 | ||
| Q3 25 | — | $-0.31 | ||
| Q2 25 | — | $-0.84 | ||
| Q1 25 | — | $-1.01 | ||
| Q4 24 | — | $-0.80 | ||
| Q3 24 | — | $-0.83 | ||
| Q2 24 | — | $-1.16 | ||
| Q1 24 | — | $-1.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $1.2B |
| Total Assets | $461.5M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | — | ||
| Q3 25 | $93.3M | — | ||
| Q2 25 | $75.5M | — | ||
| Q1 25 | $95.3M | — | ||
| Q4 24 | $98.7M | — | ||
| Q3 24 | $162.3M | — | ||
| Q2 24 | $177.9M | — | ||
| Q1 24 | $168.8M | — |
| Q4 25 | $341.7M | $1.2B | ||
| Q3 25 | $378.6M | $1.1B | ||
| Q2 25 | $377.6M | $1.1B | ||
| Q1 25 | $379.6M | $692.5M | ||
| Q4 24 | $395.7M | $699.7M | ||
| Q3 24 | $385.5M | $696.2M | ||
| Q2 24 | $389.1M | $692.5M | ||
| Q1 24 | $392.6M | $696.2M |
| Q4 25 | $461.5M | $1.3B | ||
| Q3 25 | $494.9M | $1.3B | ||
| Q2 25 | $493.3M | $1.3B | ||
| Q1 25 | $482.6M | $872.1M | ||
| Q4 24 | $499.5M | $885.0M | ||
| Q3 24 | $491.2M | $877.9M | ||
| Q2 24 | $483.7M | $878.6M | ||
| Q1 24 | $492.1M | $942.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $25.4M |
| Free Cash FlowOCF − Capex | $-1.8M | $13.0M |
| FCF MarginFCF / Revenue | -2.9% | 11.5% |
| Capex IntensityCapex / Revenue | 1.6% | 10.9% |
| Cash ConversionOCF / Net Profit | — | 2.77× |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $35.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $25.4M | ||
| Q3 25 | $-3.9M | $31.4M | ||
| Q2 25 | $108.0K | $15.3M | ||
| Q1 25 | $-125.0K | $15.0M | ||
| Q4 24 | $2.0M | $13.5M | ||
| Q3 24 | $13.2M | $8.2M | ||
| Q2 24 | $6.2M | $-181.0K | ||
| Q1 24 | $4.0M | $1.7M |
| Q4 25 | $-1.8M | $13.0M | ||
| Q3 25 | $-4.6M | $26.3M | ||
| Q2 25 | $-1.5M | $-2.9M | ||
| Q1 25 | $-974.0K | $-1.3M | ||
| Q4 24 | $1.1M | $-2.4M | ||
| Q3 24 | $12.2M | $-6.7M | ||
| Q2 24 | $5.2M | $-2.7M | ||
| Q1 24 | $3.4M | $-1.2M |
| Q4 25 | -2.9% | 11.5% | ||
| Q3 25 | -8.7% | 31.5% | ||
| Q2 25 | -3.2% | -4.2% | ||
| Q1 25 | -2.3% | -2.1% | ||
| Q4 24 | 1.9% | -3.5% | ||
| Q3 24 | 23.7% | -11.6% | ||
| Q2 24 | 11.0% | -6.3% | ||
| Q1 24 | 7.6% | -3.6% |
| Q4 25 | 1.6% | 10.9% | ||
| Q3 25 | 1.3% | 6.1% | ||
| Q2 25 | 3.5% | 26.2% | ||
| Q1 25 | 2.0% | 27.0% | ||
| Q4 24 | 1.6% | 23.3% | ||
| Q3 24 | 2.0% | 25.7% | ||
| Q2 24 | 2.3% | 5.8% | ||
| Q1 24 | 1.3% | 8.8% |
| Q4 25 | — | 2.77× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
SITM
Segment breakdown not available.
